Clinical Trial Detail

NCT ID NCT01857193
Title Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

progesterone-receptor positive breast cancer

estrogen-receptor positive breast cancer

Therapies

Everolimus + Exemestane + Ribociclib

Exemestane + Ribociclib

Age Groups: adult senior

Additional content available in CKB BOOST